HIV infects white blood cells and can hide from our immune system within them.  Current therapy can target replicating virus, but does not eliminate the infected cells.  These infected white blood cells are what prevent any current drugs from curing HIV infection.  It has been found that efficient HIV-1 infection and spreading requires T-cells expressing LFA-1 and T-cells with activated LFA-1 are more susceptible to HIV-1 infection.  Thus, HIV-infected cells are marked with higher levels of activated LFA-1, making them good targets for Leukothera™.  In preclinical studies, Leukothera™ is able to deplete HIV-infected cells ex vivo from patients with active HIV infection.